“Xylazine: Where are the Market Gaps?”

This event has already concluded. Please click on the "Register" link to view the recording. The veterinary tranquilizer xylazine is being associated with a rising count of overdose fatalities across the country amidst the ongoing crisis of drug addiction and overdose. Persons are often exposed to xylazine unintentionally through adulterated heroin/fentanyl products. Data on this important public health threat are just emerging and suggest that xylazine exposure changes the experience of fentanyl and may lead to medical consequences such as skin ulcers. There exist pressing gaps in surveillance and medical treatment of xylazine, which Dr. Kelly Dunn will explore in this webinar, focusing on areas where inventive solutions are urgently required.